Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Vitalik: Current prediction markets lack social significance; I have personally made money by betting against the FOMO in the market.

Vitalik: Current prediction markets lack social significance; I have personally made money by betting against the FOMO in the market.

BlockBeatsBlockBeats2026/01/28 04:43
Show original

BlockBeats news, on January 28, Ethereum founder Vitalik Buterin stated in an interview with ForsightNews that the markets currently being heavily promoted on the Polymarket platform include topics such as "Which team will win next week" or "Will the Bitcoin price go up or down in an hour." In the long run, these short-term bets actually do not have much social significance. In theory, prediction markets are successful as a tool, but we need more meaningful applications.


Vitalik said that last year he used a principal of $440,000 and made $70,000 on Polymarket. The method was to look for markets that had fallen into "crazy mode" and then bet that "crazy things won't happen." When market sentiment falls into an irrational "crazy mode," betting on the opposite side usually makes money.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage